Respiratory syncytial virus (RSV) causes annual epidemics of respiratory infection. Usually harmless to adults, the RSV infection can be dangerous to children under 3 years of age and elderly people over 65 years of age, often causing serious problems, even death. At present, there are no vaccines and specific chemotherapeutic agents for the treatment of this disease, so the search for low-molecular weight compounds to combat RSV is a challenge. In this work, we have shown, for the first time, that monoterpene-substituted arylcoumarins are efficient RSV replication inhibitors at low micromolar concentrations. The most active compound has a selectivity index of about 200 and acts most effectively at the early stages of infection. The F protein of RSV is a potential target for these compounds, which is also confirmed by molecular docking and molecular dynamics simulation data.
In this study nine coumarin-3-carboxamide derivatives 3a-3i were synthesized with coumarin-3-carboxylic acid chloride and different amines. Two of them, 3c and 3i, are original. The novel substances were purified by column chromatography, and their structures were identified by spectroscopic methods (1H NMR, 13C NMR, IR) and elemental analysis. Coumarin-3-carboxamide derivatives were evaluated antimicrobially against ten different ATTC isolates. The compound 3f was found to be the most effective compound in terms of antibacterial and antifungal activities.